Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients

By afschroeder • April 13, 2026

Valle LF, Romero-Kalbasi T, Jiang T, van Dams R, Fuller DB, Loblaw A, Kennedy T, Collins SP, Sharma V, Suy S, Murthy V, Mallick I, Nickols NG, Desai N, Hannan R, Aghdam N, Kaplan ID, Stephans K, Tendulkar R, Lau S, Taparra K, Steinberg ML, Kishan AU. Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients. Eur Urol Oncol. 2026 Apr 10:S2588-9311(26)00078-7. doi: 10.1016/j.euo.2026.03.019. Epub ahead of print. PMID: 41966956.

Tags: DOM STAT, Dose escalation, General Internal Medicine, High-risk prostate cancer, hormone therapy, Publications, Radiotherapy, SBRT, Stereotactic body radiotherapy

Emerging quantitative CCTA imaging biomarkers for cardiovascular risk stratification: a narrative review

Mora R, Irannejad K, Abbas N, Mogga P, Iskander B, Hubbard L, Roy S, Lakshmanan S, Budoff M, Krishnan S. Emerging quantitative CCTA imaging biomarkers[...]

Matching Primary Care and Integrated Mental Health Visits by Care Modality and Linkage to Same-Day Services for Veterans

Bonilla AG, Lov D, Haderlein TP, Jackson NJ, Leung LB. Matching Primary Care and Integrated Mental Health Visits by Care Modality and Linkage to Same-Day[...]

South Asian Cardiovascular Risk: Role of Coronary Artery Calcium Scoring and Computed Tomography Angiography

Kalra DK, Vedamurthy D, Hosadurg N, Goyal A, Gupta M, Pagidipati N, Slipczuk L, Dey D, Mehta A, Joshi P, Baskaran L, Wong N, Virani[...]